NasdaqGS - Delayed Quote USD
Cogent Biosciences, Inc. (COGT)
At close: October 18 at 4:00 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
--
--
--
--
7,871.00
--
Operating Expense
244,599.00
208,130.00
147,839.00
75,551.00
43,160.00
--
Operating Income
-244,599.00
-208,130.00
-147,839.00
-75,551.00
-35,289.00
--
Net Non Operating Interest Income Expense
17,518.00
13,077.00
3,989.00
467.00
144.00
--
Other Income Expense
36.00
2,643.00
3,609.00
2,811.00
-39,663.00
--
Pretax Income
-227,045.00
-192,410.00
-140,241.00
-72,273.00
-74,808.00
--
Net Income Common Stockholders
-227,045.00
-192,410.00
-140,241.00
-72,273.00
-179,208.00
--
Diluted NI Available to Com Stockholders
-227,045.00
-192,410.00
-140,241.00
-72,273.00
-179,208.00
--
Basic EPS
-2.49
-2.42
-2.39
-1.65
-16.17
--
Diluted EPS
-2.49
-2.42
-2.39
-1.65
-16.17
--
Basic Average Shares
91,791.51
79,657.94
58,739.71
43,805.92
11,081.26
--
Diluted Average Shares
91,791.51
79,657.94
58,739.71
43,805.92
11,081.26
--
Total Operating Income as Reported
-244,599.00
-208,130.00
-147,839.00
-75,551.00
-82,199.00
--
Total Expenses
244,599.00
208,130.00
147,839.00
75,551.00
43,160.00
--
Net Income from Continuing & Discontinued Operation
-227,045.00
-192,410.00
-140,241.00
-72,273.00
-74,808.00
--
Normalized Income
-227,045.00
-192,410.00
-140,241.00
-72,273.00
-35,391.00
--
Interest Income
17,518.00
13,077.00
3,989.00
467.00
144.00
--
Net Interest Income
17,518.00
13,077.00
3,989.00
467.00
144.00
--
EBIT
-244,599.00
-208,130.00
-147,839.00
-75,551.00
-35,289.00
--
EBITDA
-240,804.00
-204,542.00
-141,961.00
-73,560.00
-34,569.00
--
Reconciled Depreciation
3,795.00
3,588.00
5,878.00
1,991.00
720.00
--
Net Income from Continuing Operation Net Minority Interest
-227,045.00
-192,410.00
-140,241.00
-72,273.00
-74,808.00
--
Total Unusual Items Excluding Goodwill
--
--
--
--
-39,417.00
78.00
Total Unusual Items
--
--
--
--
-39,417.00
78.00
Normalized EBITDA
-240,804.00
-204,542.00
-141,961.00
-73,560.00
4,848.00
--
12/31/2019 - 3/29/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
SYRE Spyre Therapeutics, Inc.
32.76
0.00%
DNTH Dianthus Therapeutics, Inc.
29.05
+3.64%
IRON Disc Medicine, Inc.
50.56
+0.14%
PHVS Pharvaris N.V.
21.20
-0.24%
VRDN Viridian Therapeutics, Inc.
24.98
+2.97%
REPL Replimune Group, Inc.
11.53
+1.95%
CGEM Cullinan Therapeutics, Inc.
16.77
-3.45%
CRGX CARGO Therapeutics, Inc.
22.22
+2.40%
AVTE Aerovate Therapeutics, Inc.
2.3700
+2.16%
PEPG PepGen Inc.
8.94
+0.79%